Actimed Therapeutics appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle wasting disorders

• Fabio Dorigotti brings over 25 years of clinical development experience
• Joins Actimed following retirement of Frank Misselwitz

London, UK – 16 January 2025. Actimed Therapeutics, a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces the appointment of Dr Fabio Dorigotti as Chief Medical Officer (CMO) following the retirement of previous CMO, Frank Misselwitz MD.

Prior to joining Actimed, Dr Dorigotti was CMO of Swiss biopharmaceutical company Quercis Pharma. He brings over 25 years of pharmaceutical industry experience spanning the full breadth of the clinical development process.

Robin Bhattacherjee, Actimed CEO, commented: “I am very pleased to welcome Fabio as our new Chief Medical Officer as we focus on advancing our lead candidate ACM001.1 (S-pindolol benzoate) for cancer cachexia into late-stage clinical development. Fabio brings a wealth of relevant knowledge and experience and a proven track record of success. I would also like to take this opportunity to thank our retiring CMO Frank Misselwitz for his invaluable contribution to Actimed over the last several years and am delighted that he will retain his role as a Non-Executive Director on the Board of the company.”

During his career, Dr Dorigotti has held inhouse roles of Head of Global Medical Affairs for CSL Vifor and Medical Affairs Director at Astrazeneca, and as Chief Strategy Officer and President of Global Clinical for Worldwide Clinical Trials, a full-service global contract research organization (CRO). He brings a strong track record of successful clinical development and product marketing approvals, alongside a deep understanding of FDA, EMA and other regulatory agencies.

Dr Dorigotti commented: “Joining Actimed as CMO provides me with an exciting opportunity to bring my skills and experience to bear in the further development of products that could fill an unmet medical need and benefit patients with serious muscle wasting disorders. I look forward to collaborating with the excellent team at Actimed to help drive the further progress of this exciting candidate and the company.”